跳至主要内容
临床试验/EUCTR2004-001500-13-IT
EUCTR2004-001500-13-IT进行中(未招募)不适用

An 8-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the Acute Treatment of DSM-IV Generalized Anxiety Disorder in Outpatients.

PFIZER0 个研究点开始时间: 2005年6月27日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
PFIZER

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 未提供

研究者

发起方
PFIZER

相似试验

已完成
3 期
Determine if quetiapine fumarate extended-release (quetiapine XR or SEROQUEL® XR) 150 to 300 mg/day taken by itself is effective and safe in treating children or adolescents aged 10 to 17 with bipolar depression and if so, how it compares with placebo (a non-active tablet, like a sugar pill, that looks like quetiapine).
CTRI/2009/091/000696AstraZeneca194
已完成
Unknown
A 8 week, Multi-center, Randomized, Double-Blind, Placebo-Controlled Human Study for the Evaluation of the Efficacy and Safety of PMEC on Gingival health
KCT0008940MedibioLAB100
进行中(未招募)
不适用
An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertensioHypertension
EUCTR2006-000774-70-GBovartis Pharma Services AG2,252
进行中(未招募)
不适用
An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertensioHypertension
EUCTR2006-000774-70-SEovartis Pharma Services AG2,252
进行中(未招募)
不适用
An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertensioHypertension
EUCTR2006-000774-70-GRovartis Pharma Services AG2,252
An 8-Week, Multicenter, Randomized, Double-Blind,... | 临床试验